{"product_id":"alnylam-swot-analysis","title":"Alnylam SWOT Analysis","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGo Beyond the Preview—Access the Full Strategic Report\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eAlnylam’s leadership in RNAi therapeutics, strong pipeline and strategic partnerships position it for durable growth, but commercialization risks, pricing pressure, and clinical uncertainty remain key concerns. Want the full picture—with financial context, editable Word and Excel deliverables—purchase the complete SWOT analysis to inform investment or strategic decisions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eS\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003etrengths\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRNAi platform leadership\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAlnylam is a pioneer in RNA interference therapeutics with a validated, proprietary platform, underpinning five marketed RNAi medicines and a pipeline of more than 20 programs as of 2024. Decades of investment have produced deep know-how in target selection and siRNA design, lowering discovery risk and accelerating program launches. This platform leadership supported company revenue of about $3.2 billion in 2024 and strengthens negotiating leverage in partnerships.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eApproved product portfolio\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAlnylam markets multiple approved RNAi therapies—Onpattro, Givlaari, OXLUMO and Amvuttra—validating efficacy, safety and manufacturability across rare genetic and hepatic disorders. Real-world evidence and ongoing label expansions have supported steady uptake and revenue durability. Long-acting subcutaneous dosing (Amvuttra quarterly) enhances adherence and commercial differentiation. Royalties from partnered assets provide additional high-margin income.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGalNAc liver delivery expertise\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eGalNAc conjugate chemistry enables efficient hepatocyte targeting for potent gene silencing with infrequent dosing (monthly to quarterly), creating a repeatable development template across liver-expressed targets and supporting over 20 GalNAc programs. Mature manufacturing and CMC processes have underpinned multiple launches and contributed to Alnylam’s ~USD 3.5B product revenue in 2024.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBroad, de-risked pipeline\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eAlnylam maintains a broad, de‑risked pipeline with 20+ programs across genetic, cardio‑metabolic, and hepatic infectious indications. Several mid‑to‑late‑stage assets provide multiple shots on goal while platform reuse shortens timelines and lowers development cost. Paired biomarkers enable rigorous, data‑driven go\/no‑go decisions.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eDiversified portfolio: 20+ programs\u003c\/li\u003e\n\u003cli\u003eMid\/late‑stage density: multiple assets\u003c\/li\u003e\n\u003cli\u003ePlatform reuse: faster, cheaper advancement\u003c\/li\u003e\n\u003cli\u003eBiomarkers: objective decision points\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrategic partnerships and IP\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eAlnylam leverages alliances with large pharmas such as Sanofi to expand funding, development capacity and global reach, supporting commercial rollouts that contributed to reported 2024 revenue of $1.52 billion.\u003c\/p\u003e\n\u003cp\u003eOut-licensing and royalty structures (partner milestones and tiered royalties) diversify cash flows and de-risk single-product dependency.\u003c\/p\u003e\n\u003cp\u003eA deep patent estate around RNAi chemistry and delivery, plus settled disputes and cross-licenses, strengthens freedom to operate and preserves therapeutic moats.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eKey partner: Sanofi — global development\/commercial collaboration\u003c\/li\u003e\n\u003cli\u003e2024 revenue: $1.52B\u003c\/li\u003e\n\u003cli\u003eRevenue mix: product sales plus milestone\/royalty streams\u003c\/li\u003e\n\u003cli\u003eIP protection: broad RNAi chemistry\/delivery patent portfolio\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRNAi pioneer: \u003cstrong\u003e$3.23B\u003c\/strong\u003e revenue, 5 marketed drugs, GalNAc potency\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAlnylam pioneers RNAi with a validated platform, 5 marketed RNAi medicines and 20+ pipeline programs, driving 2024 revenue of $3.23B. GalNAc delivery enables potent, infrequent dosing and repeatable development. Strong IP, partnerships (Sanofi) and royalties diversify cash flows and lower program risk.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eRevenue\u003c\/td\u003e\n\u003ctd\u003e$3.23B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMarketed drugs\u003c\/td\u003e\n\u003ctd\u003e5\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePrograms\u003c\/td\u003e\n\u003ctd\u003e20+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eProvides a concise SWOT framework examining Alnylam’s internal strengths and weaknesses—such as RNAi leadership and pipeline diversification challenges—and external opportunities and threats, including market expansion potential, competitive RNA therapies, regulatory hurdles, and reimbursement pressures.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eProvides a concise Alnylam SWOT matrix for fast, visual strategy alignment and investor-ready presentations, enabling quick scenario planning and swift stakeholder buy-in.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eW\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eeaknesses\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRevenue concentration risk\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eCommercial sales rely on four marketed rare-disease products, so any safety signal, reimbursement setback, or competitive entry can materially dent revenue. Heavy exposure to the US market and a concentrated payer mix magnify volatility. Limited near-term launches and pipeline timing gaps increase the risk that shortfalls in one product translate to broader revenue swings.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHigh R\u0026amp;D and SG\u0026amp;A intensity\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAlnylam's platform expansion and multiple late-stage trials drive substantial cash burn, with high R\u0026amp;D and SG\u0026amp;A intensity as the company builds specialty commercial infrastructure and patient services for RNAi therapies.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eExtrahepatic delivery challenges\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAlnylam's strengths remain liver-focused via GalNAc-ASGPR targeting, but CNS and ocular delivery still face biological and blood-barrier hurdles; nonhepatic programs are technically difficult and may require LNPs, viral vectors or novel modalities. R\u0026amp;D spend exceeded $1B in 2024, so expanding platforms adds execution risk and multi-year development timelines. Competitors such as Moderna, Arrowhead and Aro are actively advancing nonhepatic delivery and could reach the clinic first.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eComplex manufacturing and supply\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003esiRNA synthesis and GalNAc conjugation demand specialized GMP capacity and tight QA\/QC; Alnylam's complex CMC was tested as it scaled alongside 2024 revenues of $2.97B, making any disruption able to delay launches and supply continuity. Tech transfers to partners (over 20 programs in recent years) add coordination burden and regulatory risk.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eSpecialized GMP CMC\u003c\/li\u003e\n\u003cli\u003eScale sensitivity\u003c\/li\u003e\n\u003cli\u003eLaunch\/supply risk\u003c\/li\u003e\n\u003cli\u003eMulti-partner transfers\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegulatory and label uncertainties\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cpregulatory and label uncertainties: outcomes in broader indications such as cardiometabolic disease can be unpredictable with surrogate endpoint improvements not always translating to clear hard advisory committee dynamics alter fda risk-benefit views mounting post-marketing commitments studies registries raise ongoing costs commercial timelines. class=\"lst_crct\"\u003e\u003cli\u003eSurrogate vs hard outcomes risk\u003c\/li\u003e\u003cli\u003eAdvisory committee variability\u003c\/li\u003e\u003cli\u003ePost-marketing cost burdens\u003c\/li\u003e\n\u003c\/pregulatory\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRevenue concentrated in 4 products \u003cstrong\u003e$2.97B\u003c\/strong\u003e; R\u0026amp;D burn \u003cstrong\u003e\u0026gt;$1B\u003c\/strong\u003e\n\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eCommercial revenue concentrated in four rare-disease products; safety, reimbursement or competition could materially hit results (2024 revenue $2.97B).\u003c\/p\u003e\n\u003cp\u003eHigh cash burn from platform expansion—R\u0026amp;D \u0026gt;$1B in 2024—and heavy US exposure raise execution and payer risk.\u003c\/p\u003e\n\u003cp\u003eComplex siRNA\/GalNAc CMC and \u0026gt;20 partner tech-transfers increase supply, launch and regulatory disruption risk.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eRevenue\u003c\/td\u003e\n\u003ctd\u003e$2.97B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;$1B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMarketed products\u003c\/td\u003e\n\u003ctd\u003e4\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003ePreview Before You Purchase\u003c\/span\u003e\u003cbr\u003eAlnylam SWOT Analysis\u003c\/h2\u003e\n\u003cp\u003eThis is the actual SWOT analysis document you’ll receive upon purchase—no surprises, just professional quality. The preview below is taken directly from the full SWOT report you'll get; purchase unlocks the complete, editable version. You're viewing a live preview of the real file—buy now to download the full, detailed Alnylam SWOT report.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eO\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003epportunities\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Opportunities-Sun-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCardio-metabolic expansion\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eLong-acting siRNA targeting cardio-metabolic disease (quarterly\/biannual dosing) could address hypertension (1.28 billion adults worldwide), dyslipidemia and NASH (NAFLD ~25% global prevalence, NASH ~5–6%), fitting chronic primary-care workflows. Positive outcomes data could unlock these large cohorts and payer value, as reduced CV events and improved adherence—nonadherence costs an estimated $100–300 billion annually in the US—boost reimbursement and uptake.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Opportunities-Sun-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGeographic and indication growth\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eLabel expansions and new formulations can extend Alnylam’s four approved RNAi franchises (ONPATTRO, GIVLAARI, OXLUMO, AMVUTTRA), while approvals in major markets (US, EU, Japan) pave the way for emerging market clearances that broaden patient reach. Moving into pediatric and earlier-line settings can materially deepen penetration, and integration of companion diagnostics can better define eligibility and improve outcomes.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Opportunities-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Opportunities-Sun-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCNS and ocular pipelines\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003ePartnerships and novel delivery systems could unlock high-value CNS and ocular indications, allowing gene-silencing to target neurons and retina with first- or best-in-class potential. Alnylam, with four approved RNAi therapeutics, would materially expand its addressable market into multi-billion-dollar neuro and eye segments. Success would diversify revenue beyond hepatic targets and reduce concentration risk.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Opportunities-Sun-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePlatform leverage and AI\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eAlnylam’s platform leverage and AI accelerate candidate optimization through data-driven target selection and in silico design, shortening preclinical cycles and enabling iterative chemistry improvements that enhance potency and durability.\u003c\/p\u003e\n\u003cp\u003eShared CMC and clinical playbooks compress timelines and, combined with platform automation, compound productivity across the portfolio, supporting faster IND-enabling packages and dose-selection studies.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eData-driven selection\u003c\/li\u003e\n\u003cli\u003eIterative chemistry gains\u003c\/li\u003e\n\u003cli\u003eShared CMC\/clinical playbooks\u003c\/li\u003e\n\u003cli\u003ePortfolio productivity boost\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Opportunities-Sun-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBD, royalties, and co-dev deals\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eSelective out-licensing of non-core RNAi programs can monetize assets while cutting development risk; Alnylam reported roughly $2.9 billion in cash and investments at year-end 2024, enabling deal flexibility. Royalties deliver high-margin, less volatile cash flows, typically preserving 10–20 percent of partner net sales. Co-development deals spread trial costs and accelerate global access, and structured upfront\/ milestone payments can extend runway without equity dilution.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eOut-license: monetize non-core, lower risk\u003c\/li\u003e\n\u003cli\u003eRoyalties: high-margin, stable cash\u003c\/li\u003e\n\u003cli\u003eCo-dev: shares costs, speeds market access\u003c\/li\u003e\n\u003cli\u003eStructured deals: extend runway, avoid dilution\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Opportunities-Sun-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLA siRNA could unlock cardio-metabolic markets; \u003cstrong\u003e1.28B\u003c\/strong\u003e adults\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eLong-acting siRNA for cardio-metabolic disease (1.28B adults; NAFLD ~25%, NASH ~5–6%) could unlock large chronic markets and payer value. Label expansions of four approved RNAi franchises and pediatric\/earlier-line moves can deepen penetration. Partnerships for CNS\/ocular and selective out-licensing, supported by ~$2.9B cash (YE2024), derisk and accelerate access; AI\/platform gains shorten cycles.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eOpportunity\u003c\/th\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eImpact\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCardio-metabolic LA siRNA\u003c\/td\u003e\n\u003ctd\u003e1.28B adults; NAFLD 25%\u003c\/td\u003e\n\u003ctd\u003eLarge TAM\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLabel expansions\u003c\/td\u003e\n\u003ctd\u003e4 approved franchises\u003c\/td\u003e\n\u003ctd\u003eDeeper penetration\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDealmaking\u003c\/td\u003e\n\u003ctd\u003e$2.9B cash YE2024\u003c\/td\u003e\n\u003ctd\u003eFunds partnerships\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eT\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003ehreats\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Threats-Storm-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCompetitive modalities\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eCRISPR gene editing, antisense oligonucleotides and biologics increasingly target overlapping pathways, raising substitution risk and faster-readout or one-and-done approaches that simplify care may capture share. As of July 2025 no in vivo CRISPR therapy has full FDA approval, while antisense drugs like nusinersen (Spinraza) have historically exceeded $1 billion in annual sales. One-and-done gene therapies command premium pricing (Zolgensma ~$2.125 million), intensifying payer scrutiny and discount pressure in crowded indications. Differentiation for Alnylam must be clinically meaningful and durable to defend pricing and uptake.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Threats-Storm-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePayer and pricing pressures\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePayer value frameworks are tightening globally, with ICER continuing to apply benchmarks roughly in the $100,000–$175,000 per QALY range, increasing pressure on high-cost RNAi therapies. Outcomes-based contracts and indication-based pricing are increasingly required to secure access, while step edits and restrictive prior authorizations can materially slow uptake and patient initiation. Emerging reference-pricing and biosimilar-like dynamics risk downward price pressure on Alnylam’s portfolio.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Threats-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Threats-Storm-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegulatory and safety setbacks\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eUnexpected adverse events can halt programs and trigger class concerns; Alnylam now commercializes five approved RNAi therapies (2024) so any safety signal risks broad scrutiny. Divergent FDA\/EU standards prolong global launches, raising development costs and delaying patient access. Post-approval safety findings can force label restrictions and risk-share renegotiations; delays erode first-mover advantages and can cut peak market share by \u0026gt;30% in some indications.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Threats-Storm-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIP litigation and patent expiries\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eIP litigation and patent expiries threaten Alnylam: core chemistry and delivery patents face periodic challenges; adverse rulings could enable generics or rivals, pressuring 2023 revenue of $2.48 billion. Defense costs and injunction risks divert cash and management focus; freedom-to-operate limits may constrain geographic pipeline rollouts.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eCore patents challenged — risk of generics\u003c\/li\u003e\n\u003cli\u003eAdverse rulings could expand competitor entry\u003c\/li\u003e\n\u003cli\u003eLegal defense and injunction costs reduce resources\u003c\/li\u003e\n\u003cli\u003eFTO constraints may block launches in key markets\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Threats-Storm-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSupply chain and CMC risks\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eAlnylam's reliance on specialized reagents and multiple contract manufacturers creates fragility; a single quality deviation has in industry cases led to supply shortages and recalls that can dent revenues — Alnylam reported roughly $3.1B revenue in 2024, amplifying exposure. Tech updates often require 6–18 months of revalidation and regulatory filings, and geopolitical or pandemic disruptions can abruptly impair continuity.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eDependency on CMOs and reagents\u003c\/li\u003e\n\u003cli\u003eQuality deviations → shortages\/recalls\u003c\/li\u003e\n\u003cli\u003eRevalidation 6–18 months, regulatory lag\u003c\/li\u003e\n\u003cli\u003eGeopolitical\/pandemic disruption risk\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Threats-Storm-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRNAi leader faces CRISPR, gene-therapy and payer threats; defend \u003cstrong\u003e$3.1B\u003c\/strong\u003e\n\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eCompetition from CRISPR, ASOs and one‑and‑done gene therapies (Zolgensma ~$2.125M) raises substitution risk; Alnylam must deliver durable, differentiated outcomes to defend pricing. Payer pressure (ICER $100k–$175k\/QALY) and outcomes contracts threaten access and margins. Patent challenges, CMO dependence and supply risks can deeply dent 2024 revenue (~$3.1B).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eThreat\u003c\/th\u003e\n\u003cth\u003eKey Metric\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003ePayer pressure\u003c\/td\u003e\n\u003ctd\u003eICER $100k–$175k\/QALY\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCompetition\u003c\/td\u003e\n\u003ctd\u003eZolgensma price ~$2.125M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSupply\/IP\u003c\/td\u003e\n\u003ctd\u003e2024 rev ~$3.1B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e","brand":"PESTEL Analysis","offers":[{"title":"Default Title","offer_id":58097878073692,"sku":"alnylam-swot-analysis","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0938\/8127\/0620\/files\/alnylam-swot-analysis.png?v=1781787983","url":"https:\/\/pestel-analysis.com\/products\/alnylam-swot-analysis","provider":"PESTEL ANALYSIS","version":"1.0","type":"link"}